Tissue turnover of collagen type I, III and elastin is elevated in the PCLS model of IPF and can be restored back to vehicle levels using a phosphodiesterase inhibitor

Respiratory Research

Volumn 17, Issue 1, 2016, Pages

  Hansen, Niels Ulrik Brandt ^a,b   Karsdal, Morten Asser ^a,b   Brockbank, Sarah ^c   Cruwys, Simon ^c   Rønnow, Sarah ^a   Leeming, Diana Julie ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Biomarkers; ex vivo; Fibrosis; IPF; Precision cut lung slices

Indexed keywords

BLEOMYCIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ELASTIN; ILOMASTAT; ISOBUTYLMETHYLXANTHINE; SODIUM CHLORIDE; PEPTIDE FRAGMENT; PHOSPHODIESTERASE INHIBITOR; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FIBROSING ALVEOLITIS; IN VIVO STUDY; LUNG SLICE; NONHUMAN; PRECISION CUT LUNG SLICE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN METABOLISM; RAT; AIRWAY REMODELING; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; LUNG; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME FACTOR; TISSUE CULTURE TECHNIQUE;

1-METHYL-3-ISOBUTYLXANTHINE; AIRWAY REMODELING; ANIMALS; BLEOMYCIN; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; ELASTIN; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE INHIBITORS; PROCOLLAGEN; PROTEOLYSIS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE CULTURE TECHNIQUES;

EID: 84978264419     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-016-0394-8     Document Type: Article

References (45)

1. Spagnolo P, Grunewald J, Bois RMD. Genetic determinants of pulmonary fibrosis: Evolving concepts. Lancet Respir Med. 2014;2:416-28. doi: 10.1016/S2213-2600(14)70047-5.
2. R.G. Jenkins, J.K. Simpson, G. Saini, J.H. Bentley, A.-M. Russell, R. Braybrooke, et al., Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study, Lancet Respir. Med. (2015). doi: 10.1016/S2213-2600(15)00048-X
3. N.U.B. Hansen, F. Genovese, D.J. Leeming, M.A. Karsdal, The importance of extracellular matrix for cell function and in vivo likeness., Exp. Mol. Pathol. (2015). doi: 10.1016/j.yexmp.2015.01.006.
4. O'Brien LE, Jou TS, Pollack AL, Zhang Q, Hansen SH, Yurchenco P, et al. Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat Cell Biol. 2001;3:831-8.
5. Pedersen JA, Lichter S, Swartz MA. Cells in 3D matrices under interstitial flow: effects of extracellular matrix alignment on cell shear stress and drag forces. J Biomech. 2010;43:900-5.
6. Pedersen JA, Swartz MA. Mechanobiology in the third dimension. Ann Biomed Eng. 2005;33:1469-90.
7. Kirkpatrick CA, Selleck SB. Heparan sulfate proteoglycans at a glance. J Cell Sci. 2007;120:1829-32. doi: 10.1242/jcs.03432.
8. Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol. 2010;341:126-40. doi: 10.1016/j.ydbio.2009.10.026.
9. Godbout C, Follonier Castella L, Smith EA, Talele N, Chow ML, Garonna A, et al. The mechanical environment modulates intracellular calcium oscillation activities of myofibroblasts. PLoS One. 2013;8:e64560. doi: 10.1371/journal.pone.0064560.
10. Huang X, Yang N, Fiore VF, Barker TH, Sun Y, Morris SW, et al. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol. 2012;47:340-8. doi: 10.1165/rcmb.2012-0050OC.
11. Li Z, Dranoff JA, Chan EP, Uemura M, Sévigny J, Wells RG. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology. 2007;46:1246-56. doi: 10.1002/hep.21792.
12. Veidal SS, Nielsen MJ, Leeming DJ, Karsdal MA. Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model. BMC Res Notes. 2012;5:686. doi: 10.1186/1756-0500-5-686.
13. J.-P. Morin, J.-M. Baste, A. Gay, C. Crochemore, C. Corbière, C. Monteil, Precision cut lung slices as an efficient tool for in vitro lung physio-pharmacotoxicology studies, Xenobiotica. (2012). http://www.tandfonline.com.proxy.findit.dtu.dk/doi/abs/ 10.3109/00498254.2012.727043#.Vf7Ll5es1Lc(accessed September 20, 2015)
14. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000;6:324-9. doi: 10.1016/S1357-4310(00)01756-1.
15. Schmeichel KL, Weaver VM, Bissell MJ. Structural Cues from the Tissue Microenvironment Are Essential Determinants of the Human Mammary Epithelial Cell Phenotype. J Mammary Gland Biol Neoplasia. 1998;3:201-13. doi: 10.1023/a:1018751124382.
16. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2006;22:287-309. doi: 10.1146/annurev.cellbio.22.010305.104315.
17. Weigelt B, Bissell MJ. Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol. 2008;18:311-21. doi: 10.1016/j.semcancer.2008.03.013.
18. Westra IM, Pham BT, Groothuis GMM, Olinga P. Evaluation of fibrosis in precision-cut tissue slices. Xenobiotica. 2013;43:98-112. doi: 10.3109/00498254.2012.723151.
19. Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Qvist P, et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthr Cartil. 2006;14:759-68. doi: 10.1016/j.joca.2006.01.014.
20. Wang B, Chen P, Jensen A-CB, Karsdal MA, Madsen SH, Sondergaard B-C, et al. Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. BMC Res Notes. 2009;2:259. doi: 10.1186/1756-0500-2-259.
21. Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod. 2007;22:1304-9. doi: 10.1093/humrep/dem011.
22. Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes. Clin Biochem. 2010;43:1249-56. doi: 10.1016/j.clinbiochem.2010.07.025.
23. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16:616-28. doi: 10.3109/1354750X.2011.620628.
24. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43:899-904. doi: 10.1016/j.clinbiochem.2010.03.012.
25. J.H. Kristensen, L. Larsen, B. Dasgupta, C. Brodmerkel, M. Curran, M.A. Karsdal, et al., Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders., Clin. Biochem. (2015). doi: 10.1016/j.clinbiochem.2015.07.009.
26. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-87. http://www.ncbi.nlm.nih.gov/pubmed/12297042 (accessed January 14, 2015).
27. Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326:1216-9. doi: 10.1126/science.1176009.
28. Ruiz PA, Jarai G. Discoidin domain receptors regulate the migration of primary human lung fibroblasts through collagen matrices. Fibrogenesis Tissue Repair. 2012;5:3. doi: 10.1186/1755-1536-5-3.
29. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40:362-82. doi: 10.1016/j.biocel.2007.08.011.
30. Degryse AL, Lawson WE. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am J Med Sci. 2011;341:444-9. doi: 10.1097/MAJ.0b013e31821aa000.
31. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, et al. Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009;14:181-202. doi: 10.1080/13547500902777608.
32. Dancer RCA, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J. 2011;38:1461-7. doi: 10.1183/09031936.00024711.
33. Pardo A, Selman M. Role of matrix metaloproteases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012;5:S9. doi: 10.1186/1755-1536-5-S1-S9.
34. Karsdal MA, Sumer EU, Wulf H, Madsen SH, Christiansen C, Fosang AJ, et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum. 2007;56:1549-58. doi: 10.1002/art.22599.
35. Laurent GJ, Harrison NK, McAnulty RJ. The regulation of collagen production in normal lung and during interstitial lung disease. Postgrad Med J. 1988;64 Suppl 4:26-34. http://www.ncbi.nlm.nih.gov/pubmed/3076931 (accessed January 6, 2016).
36. Vrhovski B, Weiss AS. Biochemistry of tropoelastin. Eur J Biochem. 1998;258:1-18. doi: 10.1046/j.1432-1327.1998.2580001.x.
37. Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T, et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med. 2010;134:1136-42. doi: 10.1043/2009-0144-OA.1.
38. Heinz A, Taddese S, Sippl W, Neubert RHH, Schmelzer CEH. Insights into the degradation of human elastin by matrilysin-1. Biochimie. 2011;93:187-94. doi: 10.1016/j.biochi.2010.09.011.
39. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83:111-9. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2517673&tool=pmcentrez&rendertype=abstract (accessed July 1, 2015).
40. Arizmendi N, Puttagunta L, Chung KL, Davidson C, Rey-Parra J, Chao DV, et al. Rac2 is involved in bleomycin-induced lung inflammation leading to pulmonary fibrosis. Respir Res. 2014;15:71. doi: 10.1186/1465-9921-15-71.
41. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85-97. doi: 10.1183/09059180.00001111.
42. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173:769-76. doi: 10.1164/rccm.200505-717OC.
43. Shahzeidi S, Mulier B, de Crombrugghe B, Jeffery PK, McAnulty RJ, Laurent GJ. Enhanced type III collagen gene expression during bleomycin induced lung fibrosis. Thorax. 1993;48:622-8. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=464587&tool=pmcentrez&rendertype=abstract (accessed July 2, 2015).
44. Van Hoozen BE, Grimmer KL, Marelich GP, Armstrong LC, Last JA. Early phase collagen synthesis in lungs of rats exposed to bleomycin. Toxicology. 2000;147:1-13. doi: 10.1016/S0300-483X(00)00142-6.
45. Razzaque M. Bleomycin-induced pulmonary fibrosis in rat is associated with increased expression of collagen-binding heat shock protein (HSP) 47. Virchows Arch Int J Pathol. 1998;432:455-60.